Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

OPTISTEM · Optimization of stem cell therapy for clinical trials of degenerative skin and muscle diseases

FP7Status: CLOSED1 January 200931 December 2013EU funding €11,992,312

This proposal aims to develop and implement efficacy of clinical trials with adult, tissue stem cells for degenerative diseases of epithelia and skeletal muscle. Extraordinary progress in the understanding of several key features of stem cells has been rapidly translated into novel cell therapy protocols that have yielded positive results in pre-clinical models of genetic and acquired diseases and in the first clinical trials. Much remains to be done on the basic biology of stem cells to provide new tools for cell therapy trials. Also transplantation related issues, such as engraftment, angiogenesis, tissue remodeling and immune response remain to be addressed. In general, cell therapy necessitates a continuous cross-talk among biologists and clinicians as well as crossing boundaries among different tissues/diseases. Despite many structural and functional differences, epithelia and skeletal muscle share some key features such as spatially ordered cell architecture, centered on a supporting basal lamina to which stem cells are anchored. Indeed mutations in structural proteins linking the cell membrane to the basal lamina are responsible for similarly devastating diseases such as muscular dystrophies and epidermolysis bullosa. A multi-tissue approach allows jointly addressing and solving not only scientific and clinical problems but also regulatory and ethical issues related to these novel procedures. Finally, sharing high valued dedicated platforms such as large animal facilities and GMP cell culture facilities increases performance and reduces costs. Based on these considerations, a network of internationally recognized experts in muscle and epithelial cell biology, immunology, angiogenesis, and molecular pharmacology with two stem cell-based Companies has been assembled, creating a synergistic approach that will increase the chance of success for ongoing and future clinical trials with stem cells, that are integral part of this proposal.

Consortium · 20 organisations

coordinator

UNIVERSITA DEGLI STUDI DI MILANO

IT · €1,242,585

participant

UNIVERSIDAD POMPEU FABRA

ES · €410,900

participant

CANCER RESEARCH UK LBG

UK · €250,001

participant

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

FR · €510,500

participant

FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR

IT

participant

MILTENYI BIOTEC GMBH

DE · €620,200

participant

IRCCS - ASSOCIAZIONE LA NOSTRA FAMIGLIA 'ISTITUTO SCIENTIFICO EUGENIO MEDEA'

IT · €410,900

participant

DANDO WEISS & COLUCCI LIMITED

UK · €471,000

participant

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE

CH · €751,700

participant

CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS

CH · €369,200

participant

FONDAZIONE CENTRO SAN RAFFAELE

IT · €383,900

participant

HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH

DE · €70,400

participant

INSTITUT PASTEUR

FR · €872,900

participant

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

UK · €476,900

participant

UNIVERSITY COLLEGE LONDON

€324,000

participant

AGC BIOLOGICS SPA

IT · €758,900

participant

UNIVERSITA DEGLI STUDI DI MODENA E REGGIO EMILIA

IT · €1,659,000

participant

THE UNIVERSITY OF EDINBURGH

UK · €1,239,452

participant

IFOM-ISTITUTO FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS

IT · €410,900

participant

KING'S COLLEGE LONDON

UK · €758,974

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.